Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AnaBios nets funding for arrhythmia assay
November 2019
SHARING OPTIONS:

SAN DIEGO—AnaBios recently received a grant from the FDA to further develop its drug discovery platform, which utilizes cardiomyocytes. Specifically, AnaBios will use the funding to develop a preclinical biomarker to assess the pro-arrhythmia risk of drugs based on contractility measurements in human adult primary cardiomyocytes.
 
“AnaBios is honored to receive this grant from the FDA for this critical project related to cardiac safety,” Dr. Najah Abi-Gerges, vice president of Research & Development at AnaBios, said in a press release. “Because our research uses human heart cells derived from organ donors, our human cardiac platform provides direct translation to human clinical outcomes. This research project will help us further develop this critical tool for assessing cardiac safety risk in preclinical drug discovery.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.